Sleep attacks can occur without warning.
Stop driving and contact the clinician promptly if sleepiness or sudden sleep occurs. Do not abruptly stop ropinirole: rapid reduction can cause fever, rigidity and confusion. Earlier or worsening restless legs symptoms may be augmentation and need reassessment.
Warnings and precautionsIndications
Labeled indications depend on release formulation.
Labeled indications
Immediate-release tablets are indicated for Parkinson’s disease and moderate-to-severe primary restless legs syndrome. Extended-release tablets are indicated for Parkinson’s disease; do not substitute an ER Parkinson’s regimen for RLS.
Current RLS guideline context
The 2025 AASM guideline conditionally suggests against standard ropinirole use in adults with RLS because of long-term augmentation. It allows selected use when a patient values short-term relief more than long-term risks. This recommendation does not remove the immediate-release labeled indication. Assess iron status and exacerbating factors as part of RLS care; this profile is not a complete RLS treatment algorithm.
Dosage and administration
Start low and titrate to the exact indication and formulation.
Immediate-release Parkinson’s dosing
Adult start: 0.25 mg three times daily. Weekly per-dose steps are 0.5 mg in week 2, 0.75 mg in week 3 and 1 mg in week 4. Thereafter increase total daily dose by 1.5 mg weekly up to 9 mg/day, then by up to 3 mg weekly; maximum 24 mg/day. Response and tolerability govern titration.
Immediate-release RLS dosing
Take once daily 1–3 hours before bedtime. The label’s schedule is a maximum titration framework, not a requirement to escalate.
| Treatment period | Daily dose |
|---|---|
| Days 1–2 | 0.25 mg |
| Days 3–7 | 0.5 mg |
| Week 2 | 1 mg |
| Week 3 | 1.5 mg |
| Week 4 | 2 mg |
| Week 5 | 2.5 mg |
| Week 6 | 3 mg |
| Week 7 | 4 mg maximum; higher doses unestablished |
Extended-release Parkinson’s dosing and conversion
Start 2 mg once daily for 1–2 weeks; increase by 2 mg/day at weekly or longer intervals, with at least weekly assessment during titration. Maximum 24 mg/day, but selected label generally advises maintenance at ≤8 mg/day in advanced disease and ≤12 mg/day in early disease because higher studied doses showed no added benefit. Direct IR-to-ER conversion follows total DAILY IR dose; this is not a per-dose substitution.
| IR total daily dose | Initial ER daily dose |
|---|---|
| 0.75–2.25 mg | 2 mg |
| 3–4.5 mg | 4 mg |
| 6 mg | 6 mg |
| 7.5–9 mg | 8 mg |
| 12 mg | 12 mg |
| 15 mg | 16 mg |
| 18 mg | 18 mg |
| 21 mg | 20 mg |
| 24 mg | 24 mg |
Renal and hepatic dose considerations
No adjustment is specified for CrCl 30–50 mL/min. For regular hemodialysis: Parkinson’s IR starts 0.25 mg three times daily, maximum 18 mg/day; Parkinson’s ER starts 2 mg daily, maximum 18 mg/day; RLS IR starts 0.25 mg daily, maximum 3 mg/day. No supplemental postdialysis dose. Severe renal impairment without regular dialysis and hepatic impairment are unstudied; liver dysfunction may increase exposure and requires individual assessment.
Administration, interruption and discontinuation
Take either formulation with or without food. Swallow ER whole; never crush, chew or divide. Significant interruption may require retitration; do not double a missed dose. Parkinson’s IR withdrawal: reduce from three to two daily doses for 4 days, then once daily for 3 days before stopping. Parkinson’s ER is tapered over 7 days. RLS IR requires gradual daily-dose reduction without a universal label schedule. Report ER tablet residue with rapid gastrointestinal transit because release may be incomplete.
Safety
Sleep, cardiovascular, behavioral and withdrawal risks need active follow-up.
Warnings and precautions
- Sleep attacks may occur without warning, even more than a year after initiation. Significant daytime sleepiness or sleep during active tasks ordinarily warrants supervised discontinuation. Dose reduction does not reliably eliminate this risk; continued treatment requires avoiding driving and dangerous activity.
- Syncope, bradycardia and orthostatic hypotension occur, especially during initiation or dose escalation. Use caution with significant cardiovascular disease; ER can also increase blood pressure or alter heart rate.
- Hallucinations, confusion, mania or psychotic behavior may occur; major psychotic disorders ordinarily preclude treatment. Dopaminergic co-therapy can worsen dyskinesia and may need dose reduction.
- Ask specifically about gambling, spending, sexual or eating urges. New compulsive behavior may require dose reduction or discontinuation.
- Rapid reduction or cessation can cause a syndrome of fever, rigidity, altered consciousness and autonomic instability. Withdrawal anxiety, depression, insomnia, apathy, pain, fatigue or sweating can occur despite a taper and may not respond to levodopa.
- RLS augmentation means earlier onset, worsening intensity or spread beyond the legs; early-morning rebound can also occur. Reassess therapy rather than automatically escalating.
- Possible fibrotic events have been reported, but causality is unestablished. Retinal toxicity in animals and melanin binding have uncertain human significance; these findings do not establish a routine retinal testing schedule.
Contraindications
Hypersensitivity or allergic reaction to ropinirole or the selected product’s ingredients, including urticaria, angioedema, rash or itching.
Boxed warning status
The selected current U.S. immediate-release and extended-release labels have no boxed warning. Sleep attacks, syncope, behavioral changes and withdrawal remain serious labeled precautions.
Adverse reactions and overdose
Nausea, somnolence, dizziness, vomiting, fatigue and edema are reported; Parkinson’s co-therapy may cause dyskinesia or hallucinations. Rates vary by population and formulation and are not directly comparable. Overdose can produce severe dopaminergic effects, including hypotension, syncope, confusion, hallucinations and abnormal movements; seek urgent medical or Poison Help advice. Support vital signs and provide medical supportive care.
Drug interactions
CYP1A2 changes can alter exposure; sedatives add sleep risk.
Clinically relevant interactions
| Combination or change | Clinical action |
|---|---|
| CYP1A2 inhibitors such as ciprofloxacin; enzyme induction or smoking changes | Starting or stopping can change exposure; assess adverse effects and adjust if necessary. |
| Higher-dose estrogen hormone replacement | Can reduce clearance; starting or stopping may require adjustment. |
| Dopamine antagonists, including metoclopramide and antipsychotics | May reduce efficacy; assess neurologic response and psychiatric treatment together. |
| Alcohol and other sedating medicines | Additive sedation and sleep attacks; assess safety before driving. |
| Levodopa and other dopaminergic therapy | Review dyskinesia or psychotic symptoms; co-therapy reduction may be needed. |
Use in specific populations
Pediatric use and hepatic dosing are not established.
Pregnancy and lactation
Human pregnancy data are inadequate; animal studies identified developmental harm. Discuss benefit, risk and alternatives. Milk transfer and infant effects are unknown. Ropinirole suppresses prolactin and may inhibit milk production; weigh maternal need and breastfeeding benefits with potential infant effects.
Pediatric and geriatric considerations
Safety and effectiveness in children are unestablished. No age-based dose adjustment is required in older adults because treatment is individually titrated, but clearance is lower and hallucinations and other adverse reactions are more frequent in older ER trial participants. Monitor orthostasis, cognition and sleep closely.
Renal and hepatic impairment
Moderate renal impairment needs no fixed adjustment; dialysis-specific ceilings are lower and depend on indication. Severe nondialysis renal impairment is unstudied. Hepatic pharmacokinetics are unstudied and clearance may fall; do not invent a hepatic adjustment formula.
Clinical pharmacology
Dopamine receptor stimulation drives benefit and many adverse effects.
Mechanism and pharmacodynamics
Ropinirole is a non-ergot dopamine agonist, with benefit thought to involve central D2 receptor stimulation; the precise therapeutic mechanism is not established. Dopaminergic effects include prolactin suppression and impaired postural blood pressure regulation.
Pharmacokinetics
- Absorption
- IR peak about 1–2 hours; ER median peak about 6–10 hours. Oral absolute bioavailability about 45–55%.
- Distribution
- Up to 40% protein bound; apparent distribution volume about 7.5 L/kg.
- Metabolism
- Extensive hepatic metabolism, principally CYP1A2; major metabolites are inactive.
- Elimination
- Half-life about 6 hours; <10% excreted unchanged in urine. IR steady state about 2 days and ER about 4 days.
Monitoring and counseling
Ask about sleep, standing symptoms, mental changes and treatment response.
Monitoring parameters
- Assess sleepiness and sleep attacks before and throughout treatment; review sedatives and sleep disorders.
- Check blood pressure, orthostatic symptoms, fainting and falls, especially during titration; ER requires at least weekly titration follow-up.
- Ask patient and caregiver about hallucinations, impulse-control symptoms and dyskinesia.
- Review RLS timing, spread and severity for augmentation or rebound; assess iron studies and exacerbating factors within a complete RLS plan.
- Monitor during and after withdrawal; reassess smoking changes, interacting medicines and organ function.
Patient counseling information
- Confirm IR versus ER and the prescribed indication; avoid duplicate ropinirole products. Never crush ER tablets.
- Do not double missed doses or restart a prolonged interruption at the former dose without advice.
- Rise slowly. Report fainting, hallucinations, unusual urges, new sleepiness or altered RLS timing. Stop driving if sudden sleep occurs.
- Agree on a supervised taper. Fever with rigidity or confusion after a change needs urgent evaluation; report other withdrawal symptoms promptly.
Product identification
Appearance and available strengths are manufacturer-specific.
Representative oral product · Alembic IR 0.25 mg
- Form and strength
- Film-coated immediate-release tablet · 0.25 mg
- Appearance
- White, circular and biconvex
- Imprint
- H on one side; 121 on the other
- Example NDC
- 62332-030-31 · 100 tablets
Dosage forms and strengths
Selected Alembic IR strengths: 0.25, 0.5, 1, 2, 3, 4 and 5 mg. Selected Alembic ER strengths: 2, 4, 6, 8 and 12 mg. Larger prescribed ER totals may require multiple whole tablets; available single-tablet strengths are not the daily-dose ceiling.
Storage and handling
Store the selected products at 20–25°C. IR: protect from light and moisture and close tightly. ER: dispense in a tight, light-resistant container. Keep out of children’s reach and follow the selected package instructions.
References
Original sources for the clinical and product information.
- DailyMed / National Library of MedicineAlembic ropinirole immediate-release tablets
Full public manufacturer label and patient instructions; SPL version 22, effective 20260902. Product-specific directions reviewed October 1, 2026.
- DailyMed / National Library of MedicineAlembic ropinirole extended-release tablets
Full public manufacturer label and patient instructions; SPL version 3, effective 20240904. Product-specific directions reviewed October 1, 2026.
- American Academy of Sleep Medicine / Journal of Clinical Sleep MedicineAASM 2025 RLS and periodic limb movement disorder guideline
Full public guideline HTML reviewed: Recommendation 14 with supporting rationale and Good Practice Statement. Published January 15, 2025; checked October 1, 2026.